Digital Look

Welcome to Digital Look++,
you are not logged in

Sareum Holdings (SAR)

Pharma and Biotech

14.13p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
31-Dec-24	Interim	n/a	(1.33)	(0.90)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-20	0.05	(1.12)	(1.50)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-21	n/a	(1.72)	(2.30)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-22	n/a	2.58	(3.20)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-23	n/a	(4.03)	(4.70)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-24	n/a	(4.60)	(4.20)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-25	n/a	(3.76)	(2.22)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.